Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma Journal Article
| Authors: | Aung, L.; Gorlick, R.; Healey, J. H.; Shi, W.; Thaler, H. T.; Shorter, N. A.; Huvos, A. G.; Meyers, P. A. |
| Article Title: | Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma |
| Abstract: | Purpose: The prognosis for patients who develop metachronous skeletal osteosarcoma (OS) has been considered grave compared with that for patients with relapse limited to the lungs. We investigated the incidence and outcome of metachronous skeletal OS after initial treatment of the primary tumor. Patients and Methods: Twenty-three (median age 18.7 years) of 426 patients with nonmetastatic, high-grade primary OS treated at Memorial Sloan-Kettering Cancer Center (New York, NY) between February 1973 and May 2000 developed metachronous skeletal OS. Initial therapy included combination chemotherapy and surgery. Treatment of subsequent relapses consisted of chemotherapy or radiation alone or surgery with or without additional individualized chemotherapy. Results: The median time from the diagnosis of primary OS to the development of metachronous OS was 1.4 years (range, 0.2 to 11.3 years). Median survival was 1.5 years (95% confidence interval [CI], 0.8 to 6.9 years). Two- and 5-year postmetachronous overall survival was 43.5% (95% CI, 23.2% to 63.7%) and 33% (95% CI, 13% to 53%), respectively. At last follow-up (range, 0.1 to 12.8 years), five (30.4%) patients were alive with no evidence of disease (range, 1.7 to 12.8 years; median, 4.4 years). For 11 patients who developed metachronous OS 24 months or more from initial diagnosis, 5-year postmetachronous survival rate for patients receiving combined modality versus monotherapy was 83% (95% CI, 54% to 100%) and 40% (95% CI, 0% to 83%), respectively. Conclusion: In a small subset of patients who developed late metachronous OS, combined-modality therapy with surgery and aggressive chemotherapy may result in long-term postmetachronous survival. This implies that principles used in treatment of primary OS may be applied to patients with late metachronous skeletal OS. © 2003 by American Society of Clinical Oncology. |
| Keywords: | osteosarcoma; adolescent; adult; cancer survival; child; clinical article; preschool child; treatment outcome; bone neoplasms; child, preschool; bone tumor; cancer surgery; survival rate; mortality; cisplatin; doxorubicin; cancer combination chemotherapy; multimodality cancer therapy; adjuvant therapy; cancer adjuvant therapy; cancer patient; chemotherapy, adjuvant; combined modality therapy; neoadjuvant therapy; methotrexate; drug megadose; follow up; follow-up studies; cancer diagnosis; cancer incidence; cancer grading; incidence; combination chemotherapy; cyclophosphamide; pathology; ifosfamide; adjuvant chemotherapy; bleomycin; cancer relapse; neoplasms, second primary; second cancer; humans; prognosis; human; male; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 21 |
| Issue: | 2 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2003-01-15 |
| Start Page: | 342 |
| End Page: | 348 |
| Language: | English |
| DOI: | 10.1200/jco.2003.06.177 |
| PUBMED: | 12525528 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 12 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work